New cancer vaccine that trains body's immune system to destroy cancer cells shows promising results
cancer vaccine developed by Moderna Pharmaceuticals has reportedly shown encouraging results in early trials, offering new hope for cancer treatment. Utilizing mRNA technology, similar to the Covid-19 vaccines, the vaccine aims to train the immune system to target and destroy cancer cells.
Breakthrough in mRNA Technology
The vaccine, named mRNA-4359, leverages the same technology used in Covid-19 vaccines to help the immune system distinguish between healthy cells and cancerous ones. Moderna, known for its significant role in developing Covid-19 vaccines, has now extended its research to cancer treatment.
In a phase-one clinical trial, which included 19 patients with advanced solid tumors, eight patients experienced no tumor growth, and no new tumors developed during the trial. The vaccine was well tolerated by patients, with no serious side effects reported.
Expert Opinion on the Trial
Dr. Debashis Sarker, the chief investigator of the trial, highlighted the significance of the study in the fight against advanced cancers. «This study evaluating an mRNA cancer immunotherapy is an important first step in hopefully developing a new treatment for patients with advanced cancers. We have shown that the therapy is well tolerated without serious side effects and can stimulate the body's immune system in a way that could help to treat cancer more effectively,» told The Metro.
However, he added that due to the small sample size, it is too early to determine the overall effectiveness of the vaccine. «It's too early to say
